Rocket Pharmaceuticals Stock (NASDAQ: RCKTW)

Latest news for Rocket Pharmaceuticals (NASDAQ:RCKTW) Stock

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

Rocket Pharmaceuticals Inc

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) with a Buy and maintains $12 price target.

News

Price Target

Reiteration

Analyst Ratings

EYEN

HC Wainwright & Co. Reiterates Buy on Eyenovia, Maintains $12 Price Target

WIIM

GERN

Geron shares are trading lower after the company announced the departure of CCO Anil Kapur.

Taylor Morrison Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMHC#NYSE">TMHC</a>) reported quarterly earnings of $1.97 per share which beat the analyst consensus estimate of $1.90 by 3.68 percent. This is a 7.08 percent decrease over earnings of $2.12 per share from the same period last year. The company reported quarterly sales of $1.991 billion which beat the analyst consensus estimate of $1.839 billion by 8.24 percent. This is a 3.40 percent decrease over sales of $2.061 billion the same period last year.

Earnings

Earnings Beats

TMHC

Taylor Morrison Home Q2 2024 Adj EPS $1.97 Beats $1.90 Estimate, Sales $1.991B Beat $1.839B Estimate

GOOG

GOOGL

Alphabet shares are trading lower following Q2 earnings.

Perfect Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PERF#NYSE">PERF</a>) announced financial results for the three months ended June 30, 2024, the second quarter.
Total revenue was $13.9 million, compared to $12.7 million year ago, an increase of 9.6%. The increase was primarily due to growth in the revenue of AI- and AR-cloud solutions and mobile app subscriptions.
Gross profit was $11.0 million compared with $10.2 million in the year-ago quarter, an increase of 7.8%.
Despite the increase in gross profit, the gross margin slightly decreased to 79.3% for the second quarter, from 80.6% last year, primarily due to the increase in third-party payment processing fees paid to digital distribution partners such as Google and Apple related to the growth in its mobile app subscription revenue.
Net income was $0.8 million for Q2 compared to a net loss of $0.2 million. Adjusted net income was $1.3 million compared to adjusted net income of $0.9 million in 2023, an increase of 43.8%.
Operating cash flow was $2.0 million in the second quarter of 2024, compared to $2.6 million a decrease of 24.6%.
As of June 30, 2024, Perfect Corp held $120.8 million in cash and cash equivalents, compared to $122.0 million as of March 31, 2024.
Perfect Corp had 151 key customers as of June 30, 2024, compared with 152 as of March 31, 2024. The slight decrease in the number of key customers primarily resulted from specific brand clients&#8217; non-renewal of customer contracts due to financial pressure, among other factors.
As of June 30, 2024, Perfect Corp&#8217;s cumulative customer base included 686 brand clients, with over 774,000 digital stock-keeping units for makeup, haircare, skincare, eyewear, and jewelry products, compared to 666 brand clients and over 745,000 digital SKUs as of March 31, 2024.
Perfect Corp&#8217;s YouCam mobile beauty app active subscribers grew by 18.3% year-over-year, reaching a record high of over 919,000 active subscribers at the end of the second quarter of 2024.
Perfect Corp expects such legacy non-recurring revenue to become increasingly insignificant as it continues strengthening its market leadership in providing AI—and AR-based SaaS subscription solutions for brands and customers.
Based on the growth momentum in enterprise SaaS solution demands and YouCam mobile app subscriptions during the first half of 2024, Perfect Corp reiterates its expectation that the year-over-year growth rate of total revenue in 2024 would range from 12% to 16% compared to 2023.
Price Action: PERF shares closed higher by 1.85% at $2.20 at Tuesday.

Guidance

Market-Moving Exclusives

Exclusives

PERF

EXCLUSIVE: Perfect Corp's Q2 Revenue Jumps 9.6%, YouCam App Subscribers Hit Record High

Perfect's YouCam Mobile Beauty App Active Subscribers Grew By 18.3% Year-over-year, Reaching Over 919,000 Active Subscribers At The End Of The Second Quarter

Perfect Q2 Sales $13.900M Miss $14.842M Estimate, Adj. Net Income $1.3M; Co. Had Had 151 Key Customers As Of June 30, 2024 vs 152 Key Customers As Of March 31, 2024.

USNA

Usana Health Sciences shares are trading lower after the company reported worse-than-expected Q2 financial results.

Earnings Misses

NAVI

Navient Q2 2024 Adj Sales $136.000M Miss $158.667M Estimate

BMO Capital analyst Jeffrey Silber downgrades Moody's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) from Outperform to Market Perform and lowers the price target from $482 to $455.

Downgrades

BMO Capital Downgrades Moody's to Market Perform, Lowers Price Target to $455

SFL shares are trading lower after the company announced an offering of 8 million common shares.

NIVF

NewGenlvf Group shares are trading higher after the company announced steady progress in its due diligence efforts in its proposed reverse merger with COVIRIX Medical and anticipates completion by the end of August 2024.

MANH

Manhattan Associates shares are trading higher after the company reported better-than-expected Q2 financial results.

ALGM

Allegro Microsystems shares are trading lower after the company announced a primary offering of 25 million shares.

Visa shares are trading lower following a slight Q3 revenue miss.

Canadian National Railway shares are trading lower. The company reported Q2 financial results.

HC Wainwright &amp; Co. analyst Mike Colonnese reiterates Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) with a Buy and maintains $17 price target.

RIOT

HC Wainwright & Co. Reiterates Buy on Riot Platforms, Maintains $17 Price Target

Banco Santander (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.21 by 4.76 percent. The company reported $16.870 billion in sales this quarter. This is a 9.87 percent increase over sales of $15.355 billion the same period last year.

Banco Santander Q2 2024 GAAP EPS $0.22 Beats $0.21 Estimate, Sales $16.870B Up From $15.355B YoY

Seagate Technology shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 2025 guidance above estimates.

Navient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAVI#NASDAQ">NAVI</a>) reported quarterly earnings of $0.29 per share which missed the analyst consensus estimate of $0.43 by 32.56 percent.

Navient Q2 2024 Adj EPS $0.29 Misses $0.43 Estimate

Baron Health Care Fund Q2 2023 Shareholder Letter

Baron Opportunity Fund Q2 2023 Shareholder Letter

Baron Health Care Fund Q3 2023 Shareholder Letter

Rocket Pharmaceuticals: Promising, But Not A Rocket At This Valuation

Baron Health Care Fund Q4 2023 Shareholder Letter

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch

ABBV

ACLX

AMGN

AMZN

ARGNF

ARGX

ARWR

ASND

BCAP

BMYMP

BROE

CDAY

CSGP

DAVA

DCHPF

DDOG

DPHAY

DXCM

EXAS

GPCR

GTLB

HUBS

ILMN

IMVT

INDI

INSP

INTU

ISRG

LEGN

MBLY

MRNA

MRVL

MSFT

NEOG

NONOF

NVDA

NVSEF

OPSSF

PODD

RARE

RCKT

RCKTW

REGN

RGNX

RIVN

SGRY

SHOP

SNOW

SRPT

STVN

SWAV

TECH

TSLA

VEEV

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BeiGene, Ltd. - American Depositary Shares

BeiGene

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Cerevel Therapeutics Holdings, Inc. - Common Stock

Cerevel Therapeutics Hldg

Exact Sciences Corporation - Common Stock

Exact Sciences

Gilead Sciences

Genmab

Incyte

Insmed

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

Vaxcyte

Rocket Pharmaceuticals

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Trading Halt: Halt status updated at 8:00:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 6:56:37 a.m. ET - Trading Halt: Halt News Pending

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Rocket Pharmaceuticals

News

Latest news for Rocket Pharmaceuticals (NASDAQ:RCKTW) Stock

Friday, June 28, 2024

People Also Watch